October 14, 2024
NSCLC previously treated with KRAS G12C inhibitor Solid Tumor not previously treated with KRAS G12C inhibitor
This is a Phase 1/2, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy harboring mutations in the KRAS-MAPK pathways.
October 4, 2024
• ECOG 0-1
• Participants with locally advanced or metastatic NSCLC (squamous or non-squamous) who meet the following
criteria:
• a. Progressive disease after prior treatment or after following local treatment guidelines (eg, ESMO guidelines) for the standard of care (SOC) if more strict.
• b. Tested for known treatable driver mutations/alterations (eg, EGFR, ALK, and ROS1) and received at least 1 SOC targeted therapy(ies) for the known alteration, if present or after failing local treatment guidelines (eg, ESMO or study guidelines) for the SOC if more strict.
• Measurable disease based on RECIST v1.1
• Documented homozygous deletion of MTAP in a tumor detected by a validated NGS test, or absence of MTAP protein in a tumor detected by a validated IHC test.
• Adequate organ and hematological functions
• At least 1 of the following criteria for standard-of-care therapy(ies):
• a. Progression or an inadequate response to an approved SOC therapy; there is no limit to the number of prior lines of therapy
• b. No approved SOC therapy
• c. Patient intolerant to the available SOC therapy(ies)
• d. Investigator has determined that treatment with the SOC therapy is not appropriate
September 3, 2024
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and
Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
September 3, 2024
The Biorepository for Caris Life Sciences is designed for the purpose of making quality biospecimens and associated clinical data available for research studies related to advancing precision medicine and improving care for patients.
July 15, 2024
***REFERRAL ONLY*** A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
July 15, 2024
IRONMAN Registry Sub-Study: PRODIGY: Observational study to describe effectiveness of olaparib in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and carry selected homologous recombination repair gene mutations
July 15, 2024
***REFERRAL ONLY*** A Study of Zenocutuzumab (MCLA- 128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
July 15, 2024
Brightline 2- A Phase II/III, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/metastatic, MDM2 amplified, TP53 wild-type solid tumours-biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumors
July 15, 2024
**REFERRAL ONLY** A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV- 399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung
July 15, 2024
***REFERRAL ONLY***A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
July 15, 2024
A Phase 3 Randomized, Open- Label Study Of OP-1250 Monotherapy vs Standard Of Care For The Treatment Of ER+, HER2 – Advanced Or Metastatic Breast Cancer Following Endocrine And CDK 4/6 Inhibitor Therapy (Opera-01)
July 15, 2024
A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations
July 3, 2024
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors (TNG908-C101+J13)
July 3, 2024
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors (TNG908-C101+J13
July 3, 2024
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors (TNG908-C101+J13
